Home Companies Catalysts Deep Dives
Vanflyta quizartinib APPROVED
Drug Profile
ModalitySmall molecule
RoutePO
Therapy AreaOncology
Launch2023-07-20
US LOE2038-01-01
Peak Sales Est$1000M
Formulations[{"id":"vanflyta-po","doses":"26.5mg, 53mg","route":"PO","setting":"OUTPATIENT","frequency":"Once da
Companies
DSNKY (ORIGINATOR)100%
Mechanism: FLT3 inhibitor
Expert: FLT3/AXL dual inhibitor for FLT3-mutated acute myeloid leukemia.
Everyday: Blocks a mutated protein that drives certain leukemias.
Targets: ["FLT3"]
Revenue History
PeriodRevenue ($M)
2024$150M
Q4 2024$50M
Programs (1)
IndicationStageKey StudyRegional Status
FLT3+ AML 1LAPPROVEDQuANTUM-First[{"stage":"APPROVED","region":"US","approval_date":"2023-07-20"},{"stage":"APPRO
Notes
Type II FLT3 inhibitor for FLT3-ITD+ AML. First-line approval with chemo. Only FLT3 inhibitor with survival benefit in newly diagnosed AML.
Data from Supabase · Updated 2026-03-24